QPPV.COM KNOWLEDGE ASSESSMENT

Regdanvimab: Classification, Mechanism, Regulatory History and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Regdanvimab: Classification, Mechanism, EU Authorisation History and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A reviewer is examining a report from an earlier period of regdanvimab use. Which product information should support the assessment of expectedness?

The historical product information applicable to the exposure period. Only the product information for any currently authorised COVID-19 medicine. The product information of the medicine taken most recently by the patient. No product information, because the authorisation has since been withdrawn.

Question 2 of 10 Which statement about EU ICSR validity, submission timelines and follow-up is most appropriate for a historical regdanvimab case?

The product's withdrawal removes the need to apply relevant ICSR requirements. Requirements should be applied as applicable; the report should be followed up and assessed under the relevant pharmacovigilance framework. All historical cases must be submitted within a single timeline regardless of their characteristics. Submission requirements depend solely on whether the suspected reaction appears in the historical product information.

Question 3 of 10 What is the most accurate interpretation of the EU withdrawal of Regkirona's marketing authorisation in April 2025?

It was a safety-based withdrawal following identification of a newly established adverse reaction. It was requested by the marketing authorisation holder for commercial reasons and is not described as safety-based. It was an automatic consequence of evidence that regdanvimab caused COVID-19 progression. It established that the product had never been authorised for use in the EU.

Question 4 of 10 Which set of exposure details is most useful for reliable pharmacovigilance review of historical Regkirona use?

Product identity, batch or lot where available, dose, route, infusion date and time, and country. The patient's country and outcome, with no product or administration details. Only the batch number, because dose and route are not relevant for an intravenous antibody. Only the date of hospitalisation, because it determines the exposure date.

Question 5 of 10 Why should aggregate review consider changes in circulating variants, testing, access to treatment and reporting over time?

These factors can change case mix and outcome ascertainment, affecting how reported data should be interpreted. They allow spontaneous-report counts to be converted directly into incidence rates. They prove that any observed change in outcomes was caused by a variant. They are relevant only to commercial decisions, not safety review.

Question 6 of 10 Which recordkeeping approach is most consistent with an inspection-ready pharmacovigilance system for a withdrawn product?

Remove historical product information after withdrawal because it no longer applies to current prescribing. Retain records that allow reviewers to reconstruct product identity, exposure, case validity, follow-up, coding, assessments and submission decisions. Retain only the final causality conclusion, without the evidence or reasoning behind it. Treat the withdrawal notice as a substitute for individual case documentation.

Question 7 of 10 Which patient most closely matches the historical EU-authorised treatment population for Regkirona?

An adult with early COVID-19, increased risk of progression and no requirement for supplemental oxygen. An adult with COVID-19 who already requires supplemental oxygen and has advanced respiratory failure. An adult without COVID-19 who seeks pre-exposure prevention. A child with COVID-19 and no risk factors for progression.

Question 8 of 10 Which statement correctly distinguishes seriousness, expectedness and causality in case assessment?

A known reaction cannot be serious, so expectedness replaces seriousness assessment. A reaction after infusion is automatically causal, making separate causality assessment unnecessary. These are separate assessment dimensions; a known reaction may still be serious, and temporal association alone does not establish causality. Seriousness can be assessed only after causality has been confirmed.

Question 9 of 10 Which information is most important for reconstructing the clinical context of a suspected lack-of-effect report?

Baseline severity, oxygen status, symptom onset, treatment timing, test results, risk factors, co-treatments and outcome. The patient's country alone, as a reliable substitute for viral sequencing. The brand name alone, without exposure dates or disease chronology. Only whether the patient was hospitalised after treatment.

Question 10 of 10 A patient does not improve after treatment, but no sequencing or susceptibility data are available. What is the most defensible pharmacovigilance interpretation?

Record confirmed resistance because the clinical outcome was poor. Treat non-response as a clinical observation and avoid a resistance conclusion without supporting virological or laboratory evidence. Infer the variant from the patient's country and the calendar date. Assume the antibody had no biological activity in all patients treated at that time.

QPPV.com

Regdanvimab: Classification, Mechanism, Regulatory History and Pharmacovigilance Assessment

Cookie Settings